Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. - Wikidata - awgldk - TriplyDB

Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

http://www.wikidata.org/entity/Q36200911

about

Catheter-related bloodstream infection in end-stage kidney disease: a Canadian narrative review Improving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy Bacteraemia in haemodialysis patients--not always Staphylococcus aureus.Patterns of use and appropriateness of antibiotics prescribed to patients receiving haemodialysis: an observational study Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting.Clinical presentation and outcomes of cardiovascular implantable electronic device infections in hemodialysis patients.Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients.Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study The Impact of Reporting a Prior Penicillin Allergy on the Treatment of Methicillin-Sensitive Staphylococcus aureus Bacteremia.Survival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants.Development and Validation of a Clinical Prediction Rule for Bacteremia among Maintenance Hemodialysis Patients in Outpatient Settings Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Hemodialysis Tunneled Catheter-Related Infections Antimicrobial use and stewardship programs among dialysis centers.The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014.Implementing an antimicrobial stewardship program in out-patient dialysis units.Vaccines for Staphylococcus aureus and Target Populations.Association Between Staphylococcus aureus Bacteremia and Hospital Mortality in Hemodialysis Patients With Bloodstream Infection: A Multicenter Cohort From Japanese Tertiary Care Centers.Empirical combination of a β-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus aureus bacteremia, compared to vancomycin monotherapy.Rapid identification of Staphylococcus aureus directly from Bactec blood culture broth by the BinaxNOW S. aureus test.In vitro studies of the antibacterial activity of Copaifera spp. oleoresins, sodium hypochlorite, and peracetic acid against clinical and environmental isolates recovered from a hemodialysis unit.Epidemiology and management of healthcare-associated bloodstream infections in non-neutropenic immunosuppressed patients: a review of the literature.

P2860

Q26751691-96804653-27E0-44AC-8221-2A548C98704D Q26779453-3E039913-8D41-4CC7-99F7-0ABEE306C396 Q30316474-391D6629-B264-45C1-B155-F807841F6011 Q33667585-A0853148-BD37-4011-A24E-9A8F29DE568D Q33797925-FD866F03-773E-42B4-B466-B6781BE43B6F Q33801046-1324827D-9380-4AC1-926E-0FD318E4A04F Q35827804-1E1397BD-B704-44AF-B7DF-270007568D9B Q35887127-62942A4C-036D-4BD3-90CE-37D6FB18BF4D Q36026942-8B940D64-FD96-4184-9A17-6EE3B501E515 Q36082891-88591AB8-904E-42BD-91C7-FDCA716EC010 Q36157258-9EB6A360-8BE0-44CE-8274-01A8679530F1 Q36247702-BD7C468C-7737-45AC-ACBE-2929EEB413E2 Q36836505-819E969E-29B6-4A72-AB10-A05A6A4677F2 Q37563029-D1736C49-72C4-4A4B-AC9C-2BA277324280 Q37674533-FE92C84E-6030-489A-B17B-A4814B3E8605 Q38100230-D98AF9D0-C98A-4853-9662-F229928025F1 Q38132301-256BAC0A-F068-4F60-BD5C-63C1CF10EA8C Q38701628-2ACC575A-7293-474B-87E0-13F76D4BFAA1 Q38956393-BB2D4262-8D31-4FD6-91AA-019302597593 Q38961271-F12C6888-079F-4CE2-B8F9-B9F9AC2F0743 Q40215267-5F18746D-7848-42CB-A284-88BC150BD520 Q40375415-3259EBC2-95B9-4B0C-940A-A998800C87BE Q41908737-14856963-26E8-4985-A4A3-A374A99BEAA1 Q49258406-DB809A53-2109-4CF4-838E-6A2F0FC94BA7 Q55339985-0AF8B4B5-858D-4BF5-BA8E-A63081C646C0

P2860

Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

http://www.wikidata.org/entity/Q36200911

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Prevalence and outcomes of ant ...... emia in outpatients with ESRD.

@ast

Prevalence and outcomes of ant ...... emia in outpatients with ESRD.

@en

type

label

Prevalence and outcomes of ant ...... emia in outpatients with ESRD.

@ast

Prevalence and outcomes of ant ...... emia in outpatients with ESRD.

@en

prefLabel

Prevalence and outcomes of ant ...... emia in outpatients with ESRD.

@ast

Prevalence and outcomes of ant ...... emia in outpatients with ESRD.

@en

P1433

Q36200911-531786B8-D07A-4A2D-B521-9F08CBC30C8D

P1476

Q36200911-E7CAEA7E-2154-4B36-8080-E1C55A990A66

P2093

Q36200911-0454AE22-04E0-4DF4-B838-87C0BC3E1C21

Q36200911-07DB6ABA-A799-449A-B438-F1EE260664B8

Q36200911-14344106-8EEB-4B87-9E7C-379D16B94CBC

Q36200911-8CE5B74C-B7D1-4A22-84EE-52909BDEF10A

Q36200911-90065C5B-EFC9-44B6-A776-F2AE82E167F6

Q36200911-DFCE5C60-7253-40FF-8411-FD35B754E4ED

Q36200911-F6888363-D0AB-4078-B25B-7285A3166D31

P2860

Q36200911-00EB2146-D69C-484C-88F6-CFE46A381B5A

Q36200911-03B6ABB6-E888-4C5D-8B21-D54251D72C0D

Q36200911-05476E9A-61D5-41B8-992F-4584EFBCC04A

Q36200911-07C19F22-B62D-4C6A-A402-851B88A424A2

Q36200911-0826EC44-6EF7-4514-A170-E7B562C32D82

Q36200911-23542FEE-690C-4104-8C04-CC585768E5D2

Q36200911-3985E96B-B7B8-4559-95A8-6E34FC1D67BC

Q36200911-48590D91-60B2-40B0-AB7D-F68DD452EAE4

Q36200911-6FAAD782-8D40-4569-9670-2DC433ECE49F

Q36200911-8B10A82F-128E-40EE-9533-4F4AEB8FF76F

P304

Q36200911-91E9E00D-B308-483D-A63E-EECF49B30E50

P31

Q36200911-16E7299F-9712-44AD-BE66-4DE0255E3914

P356

Q36200911-B1BF54DC-133D-437B-AB03-FEAAFA46CF9F

P433

Q36200911-2BD98570-291C-460A-ADA3-30250C270BB4

P478

Q36200911-51999B82-6756-454C-9ECF-1B2D3FDFB7D7

P577

Q36200911-C0032352-E310-47CB-9911-5030B1101810

P5875

Q36200911-D6B4D42A-80ED-4759-8C09-4D38357C492A

P698

Q36200911-35340D91-4D6B-4A4F-8EB7-B55E9214346F

P932

Q36200911-A5367E8C-47EC-49BF-8A48-7FB03A20AA1C

P356

P1433

Journal of the American Society of Nephrology

P1476

Prevalence and outcomes of ant ...... emia in outpatients with ESRD.

@en

P2093

David J R Steele

http://www.w3.org/2001/XMLSchema#string

Franklin W Maddux

http://www.w3.org/2001/XMLSchema#string

H Shaw Warren

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Hymes

http://www.w3.org/2001/XMLSchema#string

Kevin E Chan

http://www.w3.org/2001/XMLSchema#string

Ravi I Thadhani

http://www.w3.org/2001/XMLSchema#string

Raymond M Hakim

http://www.w3.org/2001/XMLSchema#string

P2860

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

Staphylococcus aureus infections

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.

Vancomycin: a history.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

The role of vancomycin in the treatment paradigm.

Staphylococcus aureus infections in hemodialysis: what a nephrologist should know.

Recent changes in vancomycin use in renal failure.

P304

1551-1559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2012010050

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230699208

http://www.w3.org/2001/XMLSchema#string

P698

22904350

http://www.w3.org/2001/XMLSchema#string

P932

3431413

http://www.w3.org/2001/XMLSchema#string